Health Care · Pharmaceutical Preparations

ZTS Zoetis SEC Filings & Insider Trading Activity 2026

company
CIK 1555280129 filings
S&P 500

ZTS at a glance

Zoetis (ZTS, SEC CIK 1555280) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Zoetis (ZTS) reported revenue of $9.5 billion (up 2.3% from FY2024) and net income of $2.7 billion. Diluted EPS was $6.02.
  • As of September 30, 2026, 50 institutional investment managers tracked by SignalX reported holding Zoetis (ZTS) shares worth $11.2 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$9.5B
+2.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
50 funds
$11.2B · −4 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Cybersecurity risk with potential uninsured costs despite cybersecurity insurance coverage
  • Dependency on third-party cloud infrastructure for critical information systems operations
  • Board Audit Committee oversight of cybersecurity risk management and material incident disclosures
  • Executive leadership includes IT veterans from Biogen and Eli Lilly enhancing cybersecurity governance
  • Periodic third-party cybersecurity assessments every 18 months to evaluate controls per NIST Cybersecurity Framework

Management Discussion & Analysis

  • Revenue $9,467M for 2025, up 2% YoY from $9,256M in 2024
  • Net income $2,673M, increased 8% from $2,486M in 2024; adjusted net income $2,847M, up 6% YoY
  • Operating segments: U.S. and International; best performing not specified, but U.S. and International product diversity provides stability
  • Key risks: economic downturn, inflation impact on demand and collections; competition from generics causing 66% sales decline of Draxxin in U.S. since 2021

Business Overview

  • No new products, services, or segments introduced or emphasized in 2026 filing text
  • Strategic shifts or competitive positioning changes not disclosed in business section
  • No quantitative business metrics or operational data provided for 2026
  • Filing unusually focused on cross-references to proxy statements and governance documents, not on business operations or financial performance

AI summary of the ZTS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $2,391M, down $31M or 1% YoY, operational revenue down 2%
  • Q3 cost-of-sales margin 70.8% vs 71.2% YoY, gross margin U.S. 82.2% vs 83.2%, International 68.9% vs 68.2%
  • Best segment International: revenue $1,116M, up 4%; worst U.S.: revenue $1,246M, down 6%
  • Nine-month operating cash flow $1,880M vs $2,056M; financing outflows $2,371M, including $1,659M share repurchases
  • Headwinds: softer companion-animal demand, generic competition, tariffs, inflation, geopolitical uncertainty and foreign-exchange volatility

Risk Factors

  • No material changes to risk factors disclosed in Zoetis’s 2025 Form 10-K
  • Regulatory compliance risk: Existing 10-K risks remain incorporated by reference
  • Operational risk: Existing MD&A operating-environment risks remain relevant to results
  • Financial risk: Existing 10-K financial-condition risks remain unchanged

AI summary of the ZTS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Zoetis
  • Full-year 2026 guidance issued, providing updated outlook for investors

Item EX-99.1: Item EX-99.1

  • Q3 revenue $2.4B, down 1%; U.S. revenue $1.2B fell 6% as Companion Animal declined 8%
  • International revenue $1.1B rose 4%, led by Livestock growth of 8% reported and 9% organically
Filed Oct 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Iris Knobloch joins Zoetis’ Board effective December 1, 2026
  • Board expands from twelve to thirteen directors, increasing governance capacity

Item EX-99.12: Item EX-99.12

  • Iris Knobloch appointed Zoetis director effective December 1, 2026
  • Board expands from 12 to 13 members, adding consumer strategy and digital transformation expertise

Item 7.01: Regulation FD Disclosure

  • Zoetis announced Ms. Knobloch’s appointment on October 13, 2026
  • Exhibit 99.1 contains the appointment press release and related details
Filed Oct 8, 2026Full analysis →

Item EX-99.14: Item EX-99.14

  • Quarterly dividend declared at $0.53 per share, signaling continued shareholder cash returns
  • Record date October 30, 2026, determining eligible common shareholders

Item 7.01: Regulation FD Disclosure

  • Quarterly dividend declared at $0.53 per share
  • Payment scheduled for December 1, 2026

AI summaries of ZTS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ZTS

Don't miss the next ZTS filing

  • Alerts as it files. A push when ZTS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ZTS, by share count.
  • Ask anything. An AI agent that reads every ZTS filing and answers with sources.

ZTS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Stetter MarkAOct 30, 2026$79.72
Driscoll RimmaAOct 9, 2026$26.17
FULLER JULIEAOct 9, 2026$26.17
Lagano RoxanneAOct 9, 2026$26.17
PECK KRISTIN CAOct 9, 2026$26.17
Esch KevinAOct 9, 2026$26.17
Ferran Astorga JeannetteAOct 9, 2026$26.17
Sarbaugh KeithAOct 9, 2026$26.17

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$8.5B$9.3B$9.5B
Net Income$2.3B$2.5B$2.7B
Net Margin27.4%26.9%28.2%
Balance Sheet
Total Assets$14.3B$14.2B$15.5B
Equity$5.0B$4.8B$3.3B
ROE46.9%52.1%80.2%
Per Share
EPS-$5.47$6.02
Cash Flow
Operating CF$2.4B$3.0B$2.9B
CapEx$732.0M$655.0M$621.0M

Source: XBRL data in Zoetis (ZTS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ZTS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ZTS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202650$11.21B
Q2 202654$11.69B
Q1 202653$19.57B
Q4 202555$20.94B
Q3 202555$24.73B
Q2 202554$26.74B
Q1 202554$20.65B
Q4 202449$15.95B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 424 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ZTS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
8-KOct 13, 2026Analysis-
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
8-KOct 8, 2026Analysis-
4Oct 2, 2026--
4Sep 18, 2026--
4Sep 2, 2026--
4Aug 11, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 6, 2026Analysis-
4Jul 14, 2026--
4Jul 14, 2026--
4Jul 14, 2026--
4Jul 14, 2026--
4Jul 14, 2026--

Related Health Care companies

All Health Care →

ZTS SEC filings: frequently asked questions

Which institutions hold ZTS stock?

As of September 30, 2026, the largest Zoetis (ZTS) holders among the 13F filers tracked by SignalX were BlackRock ($2.7 billion), Vanguard Capital Management LLC ($1.8 billion), Vanguard Portfolio Management LLC ($1.6 billion), State Street Corp ($1.4 billion), Morgan Stanley ($560.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ZTS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Zoetis (ZTS) reported revenue of $9.5 billion (up 2.3% from FY2024) and net income of $2.7 billion. Diluted EPS was $6.02. The figures come from the XBRL data in the 10-K.

What are the main risks in ZTS's latest 10-K?

In the 10-K filed February 12, 2026, Zoetis (ZTS) flagged: Cybersecurity risk with potential uninsured costs despite cybersecurity insurance coverage. Dependency on third-party cloud infrastructure for critical information systems operations. (AI summary of the Risk Factors section.)

What did ZTS report in its latest 8-K?

Zoetis (ZTS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced by Zoetis.

What are the latest ZTS SEC filings?

Zoetis (ZTS) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.

What is ZTS's SEC CIK number?

Zoetis (ZTS)'s SEC Central Index Key (CIK) is 1555280. EDGAR lists every ZTS filing under that number.

Ask anything about ZTS

The research agent reads ZTS's filings, financials, insider trades and 13F holders, then answers with sources.